Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.

Inclusion Criteria

• •Histologically confirmed diagnosis of RCC with clear cell component
• •Measurable disease
• •Treated with up to 6 prior systemic therapies for advanced/recurrent disease or have become intolerant to a systemic therapy
• •Subjects with treated brain metastases must be without magnetic resonance imaging (MRI) evidence of progression for at least 8 weeks and off steroids for at least 4 weeks to be eligible
• •At least 28 days since the last chemotherapy
• •At least 28 days before the first dose of MDX 1411 since any major surgery
• •ECOG performance status 0-2
• •No known positivity for human immunodeficiency virus (HIV), Hep B or C